MALVERN, PA — Bioanalytical contract research organization Resolian has announced significant leadership changes as it continues its global expansion. Rob Stachlewitz has been named the new Chief Executive Officer, succeeding Pat Bennett, who will transition to the role of Chief Business Officer and President of Scientific Affairs. In addition, Honggang Bi has been appointed as Chairman of the board.
Backed by Ampersand Capital Partners and KKR’s Health Care Strategic Growth strategy, Resolian has rapidly expanded its presence worldwide. The company recently acquired Alliance Pharma in Malvern, Pennsylvania, UK-based Drug Development Solutions, and China-based Denali MedPharm, establishing operations across four continents. A state-of-the-art bioanalytical lab was also opened in Brisbane, Australia.
Honggang Bi, with over 30 years of experience with companies like Pfizer and Labcorp, expressed his enthusiasm for his new role: “It’s an honor to be appointed Chairman of Resolian. I am excited to work alongside Rob, Pat, the Ampersand and KKR teams, and our nearly 500 dedicated global employees.”
Rob Stachlewitz, previously Corporate Vice President and General Manager at Charles River, brings 15 years of pharmaceutical R&D experience to his new role. He will focus on enhancing Resolian’s operational capabilities and guiding its strategic growth. “With Rob’s extensive background shepherding life science businesses and teams on a global scale, we are confident that he will lead Resolian to new heights,” said Honggang Bi.
Pat Bennett has been pivotal in Resolian’s growth over the past three years. As he takes on his new responsibilities, he will concentrate on expanding service capabilities and strengthening client relationships. Dave Patteson, Partner at Ampersand Capital Partners, highlighted Bennett’s contributions, stating, “As he transitions into his new role, Pat will continue to make critical contributions to Resolian’s future growth and innovation.”
The leadership changes highlight Resolian’s efforts to provide industry-leading bioanalytical services for drug development projects globally. With a strengthened leadership team, the company is poised for continued success in the competitive bioanalytical CRO industry.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.